Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab plus systemic chemotherapy for malignant mesothelioma with pleural or peritoneal effusions
ChiCTR2200055496Phase 2Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in mesothelioma, pleural mesothelioma and peritoneal mesothelioma, sponsored by Shandong Cancer Hospital. Primary endpoints: Objective response rate and Disease control rate. Started Jan 2022; status: recruiting.
02
Drugs
bevacizumab
03
Conditions
mesotheliomapleural mesotheliomaperitoneal mesothelioma
Beyond the preview
Go deeper on ChiCTR2200055496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200055496.